Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma

被引:3
|
作者
Todica, Andrei [1 ]
Haidvogl, Sabine [1 ]
Fendler, Wolfgang Peter [1 ]
Ilhan, Harun [1 ]
Rominger, Axel [1 ]
Haug, Alexander Robert [2 ]
Bartenstein, Peter [1 ]
Lehner, Sebastian [1 ,3 ]
机构
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Marchioninistr 15, D-81377 Munich, Germany
[2] Med Univ Vienna, Div Nucl Med, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria
[3] Ambulatory Healthcare Ctr Dr Neumaier & Colleague, Radiol, Nucl Med, Radiat Therapy, Regensburg, Germany
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2017年 / 56卷 / 06期
关键词
Differentiated thyroid carcinoma; remnant ablation; radioiodine; reduced activity; outcome; RADIOACTIVE IODINE THERAPY; 2ND PRIMARY MALIGNANCIES; LONG-TERM SURVIVAL; CANCER PATIENTS; ASSOCIATION GUIDELINES; PROGNOSTIC-FACTORS; I-131; THERAPY; THYROGLOBULIN; PAPILLARY; MANAGEMENT;
D O I
10.3413/Nukmed-0922-17-08
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: To compare the success rates of radioiodine therapy (RIT) for thyroid remnant ablation (TRA) after the administration of a high-standard activity (3700 MBq; 100 mCi) to a lower-activity regimen of 2000 MBq (54 mCi) I-131 in a cohort of differentiated thyroid carcinoma (DTC) patients (papillary, follicular, mixed, pT1a(m) - pT3, N0 - NX, R0). Methods: 135 patients received approx. 2000 MBq I-131 (54 mCi) for thyroid remnant ablation after total thyroidectomy for DTC, 137 patients received approx. 3700 MBq (100 mCi) I-131. Ablation success was defined as thyroglobulin (TG) levels <0.5 ng/ml after stimulation, negative I-131 whole-body scan and inconspicuous results on neck ultrasonography approximately 6 months after initial RIT. Results: In the follow-up 84.4 % of patients in the reduced-activity group and 87.6 % of the patients in the standard-activity group did not show any relevant residual I-131 uptake in the thyroid bed (p = 0.454). 90 % in the reduced-activity group and 91 % in the standard-activity group demonstrated a stimulated TG level <0.5 ng/ml (p = 0.969). All patients were unremarkable in cervical ultrasonography. The success rate was comparable in both groups (81.5 % in the reduced-activity group vs. 83.9 % in the standard-activity group, p = 0.592). No re-therapy was required in 85.2 % of the patients in the low-activity group as compared to 87.6 % of the patients in the standard-activity group (p = 0.563). Conclusions: We could demonstrate that irrespective of the activity administered, the patients had comparable success rates with regard to TRA as defined by our criteria. We thus consider the use of a reduced-activity regimen for TRA safe and feasible in the patient cohort examined in this study.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 50 条
  • [21] Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
    Pitoia, Fabian
    Marlowe, Robert J.
    Abelleira, Erika
    Faure, Eduardo N.
    Bueno, Fernanda
    Schwarzstein, Diego
    Julio Lutfi, Ruben
    Niepomniszcze, Hugo
    [J]. JOURNAL OF THYROID RESEARCH, 2012, 2012
  • [22] Comparison of the effectiveness of radioiodine treatment in patients with differentiated thyroid cancer with low-intermediate risk
    Lopez Villar, I.
    Navarro Martinez, T.
    Castro Beiras, J.
    Martinez Lorca, A.
    Rizkallal Monton, S.
    Lorente Castro, B.
    Ajuria Illarramendi, O.
    Jane Soler, P.
    Orduna Diez, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S609 - S610
  • [23] Radioiodine low-dose for remnant ablation in differentiated thyroid carcinoma: considerations of a pilot study
    Burroni, L.
    Castagna, M. G.
    Cipri, C.
    Pacini, F.
    Vattimo, A. G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S421 - S421
  • [24] Low Radioiodine Dose in Postoperative Ablation of Residual Thyroid Tissue in Patients with Differentiated Thyroid Carcinoma
    Bourogianni, O.
    Kapsoritakis, N.
    Tsaroucha, A.
    Stahaki, M.
    Papadaki, E.
    Koukouraki, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S437 - S437
  • [25] Low-activity Radioiodine for Remnant Ablation after Surgery for Differentiated Thyroid Cancer-Initial Experience
    Sobral Violante, L. C.
    Teixeira, J.
    Sampaio, I.
    Martins, R.
    Couto, J.
    Fonseca, A.
    Costa, L.
    Lopes, F.
    Soares, O.
    Duarte, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S503 - S504
  • [26] Factors Influencing the Presence of Remnant Thyroid Tissue After Thyroidectomy for Differentiated Thyroid Carcinoma
    Derya Cayir
    Bahadir Kulah
    Mehmet Bozkurt
    Demet Yilmazer
    [J]. Indian Journal of Surgery, 2020, 82 : 50 - 56
  • [27] Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view
    Lamartina, Livia
    Cooper, David S.
    [J]. ENDOCRINE, 2015, 50 (01) : 67 - 71
  • [28] Factors Influencing the Presence of Remnant Thyroid Tissue After Thyroidectomy for Differentiated Thyroid Carcinoma
    Cayir, Derya
    Kulah, Bahadir
    Bozkurt, Mehmet
    Yilmazer, Demet
    [J]. INDIAN JOURNAL OF SURGERY, 2020, 82 (01) : 50 - 56
  • [29] Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A Systematic Review of the Literature
    Lamartina, Livia
    Durante, Cosimo
    Filetti, Sebastiano
    Cooper, David S.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (05): : 1748 - 1761
  • [30] Association of Total Thyroidectomy or Thyroid Lobectomy With the Quality of Life in Patients With Differentiated Thyroid Cancer With Low to Intermediate Risk of Recurrence
    Chen, Wanna
    Li, Jie
    Peng, Sui
    Hong, Shubin
    Xu, Heyang
    Lin, Bo
    Liang, Xiaoli
    Liu, Yihao
    Liang, Jiadong
    Zhang, Zhaoxi
    Ye, Yingnan
    Liu, Fang
    Lin, Cuiyu
    Xiao, Haipeng
    Lv, Weiming
    [J]. JAMA SURGERY, 2022, 157 (03) : 200 - 209